R
0.605
0.02 (4.13%)
| 前收盘价格 | 0.581 |
| 收盘价格 | 0.648 |
| 成交量 | 54,433 |
| 平均成交量 (3个月) | 213,446 |
| 市值 | 3,678,956 |
| 预期市盈率 (P/E Forward) | 1.43 |
| 价格/销量 (P/S) | 6.96 |
| 股市价格/股市净资产 (P/B) | 0.900 |
| 52周波幅 |
| 营业毛利率 | -102.80% |
| 营业利益率 (TTM) | -69.57% |
| 季度收入增长率 (YOY) | 382.00% |
| 总债务/股东权益 (D/E MRQ) | 914.75% |
| 流动比率 (MRQ) | 0.540 |
| 营业现金流 (OCF TTM) | -9.37 M |
| 杠杆自由现金流 (LFCF TTM) | -5.39 M |
| 资产报酬率 (ROA TTM) | -37.28% |
| 股东权益报酬率 (ROE TTM) | -1,708.61% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 看涨 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 看涨 | |
| 股票 | Redhill Biopharma Ltd. | - | - |
AIStockmoo 评分
-0.7
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -4.0 |
| 平均 | -0.71 |
|
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Growth |
| 机构持股比例 | 4.30% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合